Suppr超能文献

卡介苗联合或不联合干扰素 α-2b 与超大剂量 vs 推荐日剂量维生素用于非肌层浸润性膀胱癌诱导及维持膀胱内治疗。

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

机构信息

Department of Urology, University of Iowa, Iowa City, Iowa 52242-1089, USA.

出版信息

J Urol. 2010 Nov;184(5):1915-9. doi: 10.1016/j.juro.2010.06.147. Epub 2010 Sep 17.

Abstract

PURPOSE

In a multicenter, prospectively randomized study we evaluated bacillus Calmette-Guérin alone vs bacillus Calmette-Guérin plus interferon α-2b and megadose vitamins vs recommended daily allowance vitamins during induction and maintenance intravesical therapy in the treatment of nonmuscle invasive bladder cancer.

MATERIALS AND METHODS

Patients who were bacillus Calmette-Guérin naïve with carcinoma in situ, Ta or T1 urothelial cancer were randomized to receive intravesical bacillus Calmette-Guérin or bacillus Calmette-Guérin plus interferon α-2b. Patients were further randomized to receive a recommended daily allowance or megadose vitamin preparation. Induction bacillus Calmette-Guérin treatment was given weekly for 6 weeks, and patients who were recurrence-free received maintenance treatment at 4, 7, 13, 19, 25 and 37 months. Patients were followed with quarterly cystoscopy for 2 years, then semiannually through year 4 and then annually. The primary end point was biopsy confirmed tumor recurrence or positive cytology.

RESULTS

A total of 670 patients were accrued and randomized. At 24-month median followup recurrence-free survival was similar in all groups with 63% in the bacillus Calmette-Guérin with recommended daily allowance vitamins group, 59% in bacillus Calmette-Guérin with megadose vitamins, 55% in bacillus Calmette-Guérin/interferon α-2b with recommended daily allowance vitamins and 61% in bacillus Calmette-Guérin/interferon α-2b with megadose vitamins (p >0.05). The addition of interferon α-2b was associated with a more frequent incidence of fever (11% vs 5%) and constitutional symptoms (18% vs 11%) vs bacillus Calmette-Guérin alone (p <0.05).

CONCLUSIONS

Interferon α-2b added to bacillus Calmette-Guérin induction and maintenance intravesical therapy did not decrease tumor recurrence in bacillus Calmette-Guérin naïve cases, but was associated with increased fever and constitutional symptoms. No difference in time to recurrence was present in patients receiving recommended daily allowance vs high dose vitamins.

摘要

目的

在一项多中心、前瞻性随机研究中,我们评估了卡介苗(BCG)单独治疗与 BCG 联合干扰素-α2b 治疗以及大剂量维生素治疗与推荐的每日允许量(RDA)维生素治疗在非肌肉浸润性膀胱癌诱导和维持膀胱内治疗中的疗效。

材料和方法

我们将初治原位癌、Ta 或 T1 尿路上皮癌患者随机分为接受膀胱内 BCG 或 BCG 联合干扰素-α2b 治疗。患者进一步随机接受 RDA 或大剂量维生素制剂治疗。诱导性 BCG 治疗每周进行 6 周,无复发的患者在 4、7、13、19、25 和 37 个月时接受维持治疗。患者每 3 个月进行一次膀胱镜检查随访 2 年,然后每 6 个月随访 4 年,然后每年随访 1 次。主要终点是活检证实肿瘤复发或细胞学阳性。

结果

共纳入 670 例患者并进行了随机分组。在 24 个月的中位随访中,所有组的无复发生存率相似,BCG+RDA 维生素组为 63%,BCG+大剂量维生素组为 59%,BCG+干扰素-α2b+RDA 维生素组为 55%,BCG+干扰素-α2b+大剂量维生素组为 61%(p>0.05)。与 BCG 单药治疗相比,干扰素-α2b 的加入与更频繁的发热(11%比 5%)和全身症状(18%比 11%)相关(p<0.05)。

结论

干扰素-α2b 联合 BCG 诱导和维持膀胱内治疗不能降低初治卡介苗患者的肿瘤复发率,但与发热和全身症状增加相关。在接受 RDA 与高剂量维生素治疗的患者中,复发时间无差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验